Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis.
Kugler M, Dellinger M, Kartnig F, Müller L, Preglej T, Heinz LX, Simader E, Göschl L, Puchner SE, Weiss S, Shaw LE, Farlik M, Weninger W, Superti-Furga G, Smolen JS, Steiner G, Aletaha D, Kiener HP, Lewis MJ, Pitzalis C, Tosevska A, Karonitsch T, Bonelli M. Kugler M, et al. Among authors: simader e. Ann Rheum Dis. 2023 Sep;82(9):1142-1152. doi: 10.1136/ard-2022-223396. Epub 2023 Jun 21. Ann Rheum Dis. 2023. PMID: 37344156
Non-classical monocytes as mediators of tissue destruction in arthritis.
Puchner A, Saferding V, Bonelli M, Mikami Y, Hofmann M, Brunner JS, Caldera M, Goncalves-Alves E, Binder NB, Fischer A, Simader E, Steiner CW, Leiss H, Hayer S, Niederreiter B, Karonitsch T, Koenders MI, Podesser BK, O'Shea JJ, Menche J, Smolen JS, Redlich K, Blüml S. Puchner A, et al. Among authors: simader e. Ann Rheum Dis. 2018 Oct;77(10):1490-1497. doi: 10.1136/annrheumdis-2018-213250. Epub 2018 Jun 29. Ann Rheum Dis. 2018. PMID: 29959183 Free PMC article.
Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis.
Simader E, Tobudic S, Mandl P, Haslacher H, Perkmann T, Nothnagl T, Sautner J, Radner H, Winkler F, Burgmann H, Mrak D, Aletaha D, Winkler S, Blüml S. Simader E, et al. Ann Rheum Dis. 2022 Mar;81(3):416-421. doi: 10.1136/annrheumdis-2021-221347. Epub 2021 Nov 29. Ann Rheum Dis. 2022. PMID: 34844927
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
Bonelli M, Mrak D, Tobudic S, Sieghart D, Koblischke M, Mandl P, Kornek B, Simader E, Radner H, Perkmann T, Haslacher H, Mayer M, Hofer P, Redlich K, Husar-Memmer E, Fritsch-Stork R, Thalhammer R, Stiasny K, Winkler S, Smolen JS, Aberle JH, Zeitlinger M, Heinz LX, Aletaha D. Bonelli M, et al. Among authors: simader e. Ann Rheum Dis. 2022 May;81(5):687-694. doi: 10.1136/annrheumdis-2021-221558. Epub 2022 Jan 13. Ann Rheum Dis. 2022. PMID: 35027397 Clinical Trial.
Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study.
Mandl P, Tobudic S, Haslacher H, Karonitsch T, Mrak D, Nothnagl T, Perkmann T, Radner H, Sautner J, Simader E, Winkler F, Burgmann H, Aletaha D, Winkler S, Blüml S. Mandl P, et al. Among authors: simader e. Ann Rheum Dis. 2022 Jul;81(7):1017-1022. doi: 10.1136/annrheumdis-2021-221788. Epub 2022 Mar 18. Ann Rheum Dis. 2022. PMID: 35304407
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study.
Mrak D, Simader E, Sieghart D, Mandl P, Radner H, Perkmann T, Haslacher H, Mayer M, Koblischke M, Hofer P, Göschl L, Kartnig F, Deimel T, Kerschbaumer A, Hummel T, Kornek B, Thalhammer R, Stiasny K, Winkler S, Smolen JS, Aberle JH, Aletaha D, Heinz LX, Bonelli M. Mrak D, et al. Among authors: simader e. Ann Rheum Dis. 2022 Dec;81(12):1750-1756. doi: 10.1136/ard-2022-222579. Epub 2022 Aug 17. Ann Rheum Dis. 2022. PMID: 35977809
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial.
Mrak D, Sieghart D, Simader E, Tobudic S, Radner H, Mandl P, Göschl L, Koblischke M, Hommer N, Wagner A, Mayer M, Schubert L, Hartl L, Kozbial K, Hofer P, Kartnig F, Hummel T, Kerschbaumer A, Deimel T, Puchner A, Gudipati V, Thalhammer R, Munda P, Uyanik-Ünal K, Zuckermann A, Novacek G, Reiberger T, Garner-Spitzer E, Reindl-Schwaighofer R, Kain R, Winkler S, Smolen JS, Stiasny K, Fischer GF, Perkmann T, Haslacher H, Zeitlinger M, Wiedermann U, Aberle JH, Aletaha D, Heinz LX, Bonelli M. Mrak D, et al. Among authors: simader e. Nat Commun. 2022 Sep 12;13(1):5362. doi: 10.1038/s41467-022-33036-y. Nat Commun. 2022. PMID: 36097029 Free PMC article. Clinical Trial.
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls.
Kartnig F, Mrak D, Simader E, Tobudic S, Radner H, Mandl P, Göschl L, Hommer N, Mayer M, Hofer P, Hummel T, Deimel T, Geßl I, Puchner A, Kerschbaumer A, Thalhammer R, Handisurya A, Kain R, Winkler S, Smolen JS, Stiasny K, Perkmann T, Haslacher H, Aberle JH, Aletaha D, Heinz LX, Sieghart D, Bonelli M. Kartnig F, et al. Among authors: simader e. Ann Rheum Dis. 2023 Feb;82(2):292-300. doi: 10.1136/ard-2022-222682. Epub 2022 Sep 15. Ann Rheum Dis. 2023. PMID: 36109141 Clinical Trial.
Bona fide dendritic cells are pivotal precursors for osteoclasts.
Puchner A, Simader E, Saferding V, Hofmann M, Kieler M, Brunner J, Pfeifle R, Niederreiter B, Krönke G, Schabbauer G, Georgel P, Diehl G, Steiner G, Hayer S, Redlich K, Smolen JS, Aletaha D, Blüml S. Puchner A, et al. Among authors: simader e. Ann Rheum Dis. 2024 Mar 12;83(4):518-528. doi: 10.1136/ard-2022-223817. Ann Rheum Dis. 2024. PMID: 38071515
34 results